Editor2026-04-24T08:28:04+00:00Waiv Achieves Dual CE Marking Under IVDR, Propelling AI Precision Testing for Breast and Colorectal Cancer for Clinical RoutineEditor2026-04-24T08:28:04+00:00April 17, 2026|
Editor2026-05-20T10:03:19+00:00Owkin Creates New Spin Out Waiv, Formerly Owkin Dx, with $33m FinancingEditor2026-05-20T10:03:19+00:00March 13, 2026|
Editor2025-12-08T09:53:40+00:00Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology SlidesEditor2025-12-08T09:53:40+00:00December 5, 2025|
Editor2026-05-22T14:33:55+00:00Prognostic Risk Profiling from Digitized H&E: a look at new international performances of an AI model for breast cancerEditor2026-05-22T14:33:55+00:00September 26, 2025|
Editor2025-11-04T14:08:29+00:00Owkin Partners with Istituto Europeo di Oncologia (IEO) to Advance AI-driven Cancer Research and Therapeutic DevelopmentEditor2025-11-04T14:08:29+00:00September 17, 2025|
Editor2025-08-27T12:28:21+00:00Deep Learning Assessment of Metastatic Relapse Risk From Digitized Breast Cancer Histological SlidesEditor2025-08-27T12:28:21+00:00August 13, 2025|
Editor2025-08-11T06:16:59+00:00Owkin Teams Up with NeoGenomics and France Tissue Bank to Build IHC-Dedicated Foundation Model for AI-Driven ADC DiagnosticsEditor2025-08-11T06:16:59+00:00July 30, 2025|
